Analyzing QuidelOrtho (NASDAQ:QDEL) and Trident Brands (OTCMKTS:TDNT)

Trident Brands (OTCMKTS:TDNT) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Trident Brands and QuidelOrtho, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trident Brands	0	0	0	0	0.00
QuidelOrtho	2	4	0	0	1.67

QuidelOrtho has a consensus target price of $13.62, indicating a potential downside of 22.85%. Given QuidelOrtho’s stronger consensus rating and higher possible upside, analysts clearly believe QuidelOrtho is more favorable than Trident Brands.

Profitability

This table compares Trident Brands and QuidelOrtho’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trident Brands	N/A	N/A	N/A
QuidelOrtho	-45.57%	4.25%	1.56%

Valuation & Earnings

This table compares Trident Brands and QuidelOrtho”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trident Brands	N/A	N/A	N/A	N/A	N/A
QuidelOrtho	$2.73 billion	0.44	-$1.13 billion	($17.82)	-0.99

Trident Brands has higher earnings, but lower revenue than QuidelOrtho.

Volatility and Risk

Trident Brands has a beta of -3.8, suggesting that its share price is 480% less volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Insider and Institutional Ownership

99.0% of QuidelOrtho shares are held by institutional investors. 33.9% of Trident Brands shares are held by company insiders. Comparatively, 1.1% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

QuidelOrtho beats Trident Brands on 7 of the 9 factors compared between the two stocks.

About Trident Brands

Trident Brands Incorporated, together with its subsidiaries, focuses on developing branded consumer products and ingredients in the nutritional supplement, life sciences, and food and beverage categories in the United States and Canada. The company develops, markets, and sells a portfolio of DHA supplements under the Brain Armor brand. It also holds various banking facilities; and licenses associated with the manufacturing, importation, and sale of natural health and nutrition products. The company was formerly known as Sandfield Ventures Corp. and changed its name to Trident Brands Incorporated in July 2013. Trident Brands Incorporated was incorporated in 2007 and is based in Boca Raton, Florida.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.